Barclays raised the firm’s price target on Kenvue (KVUE) to $18 from $17 and keeps an Equal Weight rating on the shares following the Q3 report. The company’s sales came in below expectations, with low incidence levels and continued destocking, the analyst tells investors in a research note. However, the firm sees “some green shoots” in Kenvue’s Skin Health and Beauty segment.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue Inc call volume above normal and directionally bullish
- Moderately bullish activity in Kenvue Inc with shares up 1.69%
- Kenvue, Inc. Faces Tax Uncertainty: Potential Risks for Shareholders if Transaction Fails IRS Reorganization Test
- BofA moves to No Rating on Kenvue after Kimberly-Clark deal
- Kimberly-Clark price target lowered to $125 from $144 at Morgan Stanley